98%
921
2 minutes
20
Study Objective: Emergency department (ED) initiation of buprenorphine for patients with opioid use disorder increases treatment engagement but remains an uncommon practice. One important barrier to ED-initiated buprenorphine is the additional training requirement (X waiver). Our objective is to evaluate the influence of a financial incentive program on emergency physician completion of X-waiver training. Secondary objectives are to evaluate the program's effect on buprenorphine prescribing and to explore physician attitudes toward the incentive.
Methods: We conducted a prospective, observational cohort study set in 3 urban academic EDs before and after implementation of a financial incentive program providing $750 for completion of X-waiver training. We describe program participation as well as rates of buprenorphine prescribing per opioid use disorder-related encounter before and after the intervention period, using electronic health record data. We also completed a postintervention physician survey assessing attitudes about the incentive program.
Results: Overall, 89% of eligible emergency physicians (56/63) completed the X-waiver training during the 6-week incentive period. In the 5 months after the incentive, buprenorphine prescribing per opioid use disorder-related encounter increased from 0.5% to 16% (Δ 15%; 95% confidence interval 10.6% to 19.9%), with substantial variability across sites (range 8% to 22% of opioid use disorder-related encounters). In a postintervention survey, 67% of participating physicians indicated that they would have completed the training for a lower amount.
Conclusion: A financial incentive paying approximately half the clinical rate was effective in promoting emergency physician X-waiver training. The effect on ED-based buprenorphine prescribing was positive but variable across sites, and likely dependent on the availability of additional supports.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.annemergmed.2020.02.020 | DOI Listing |
J Am Assoc Nurse Pract
July 2025
Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina.
Starting in 2016, physician assistants (PAs) and Advanced Practice Registered Nurses could prescribe buprenorphine with an approved waiver, which improves health care through expansion of access to care, reduction of health care costs, and provision of high-quality care. This study addresses barriers to student NP's and PA's ability to prescribe buprenorphine by examining knowledge and attitudes toward prescribing medications for opioid use disorder (MOUD), subjective norms and perceived behavioral control surrounding prescribing MOUD, and the intention to prescribe MOUD among NPs and PAs. Participants were 120 students enrolled in the NP or PA program at 3 large universities in the southeastern United States.
View Article and Find Full Text PDFCurr Geriatr Rep
May 2025
VA San Diego Healthcare System, San Diego, CA, USA.
Purpose Of The Review: The review synthesizes current literature on the epidemiology, treatment outcomes, and co-occurring conditions of opioid use disorder (OUD) in older adults, framed through the OUD cascade of care model.
Recent Findings: The prevalence of OUD among older adults has risen significantly, with Medicare data showing an increase from 4.6 to 15.
Subst Use Misuse
June 2025
Department of Family and Community Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Introduction: Despite effective treatment for opioid use disorder, access to care is limited. Increased availability of evidence-based medication for opioid use disorder (MOUD) treatment within primary care is urgently needed. This study describes efforts to increase MOUD services within a large urban primary care practice.
View Article and Find Full Text PDFAIMS Public Health
January 2025
National Opinion Research Center at the University of Chicago, 55 East Monroe St, 30th Floor, Chicago IL 60603, USA.
Despite federal legislation intended to increase the prescribing of buprenorphine as medication for opioid use disorder (MOUD), such as the Drug Addiction Treatment Act (DATA) of 2000, most providers have continued to prescribe to some patients or to not prescribe at all. We aimed to determine the continuing barriers and supports needed for expanding buprenorphine prescribing and compared barriers experienced by emergency department (ED) physicians with those in other practice settings, given the unique aspects of the ED practice setting. We obtained survey data from August through November 2021 from 412 X-waivered Illinois physicians licensed to prescribe buprenorphine as MOUD, 95 (23.
View Article and Find Full Text PDF